Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice

Leukemia

Volumn 19, Issue 12, 2005, Pages 2215-2222

  Siegler, U ^a   Kalberer, C P ^a   Nowbakht, P ^a   Sendelov, S ^a   Meyer Monard, S ^a   Wodnar Filipowicz, Aleksandra ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

AML; Antileukemia immunity; Immunotherapy; NK activating receptors; NK cells; NOD SCID mice

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLAST CELL; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL ISOLATION; CELL STRAIN K 562; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCID MOUSE;

EID: 28544432065     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403985     Document Type: Article

References (46)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187-376.
2. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640.
3. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19: 197-223.
4. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729.
5. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-133.
6. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999; 17: 875-904.
7. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004; 306: 1517-1519.
8. Bottino C, Moretta L, Pende D, Vitale M, Moretta A. Learning how to discriminate between friends and enemies, a lesson from natural killer cells. Mol Immunol 2004; 41: 569-575.
9. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850-861.
10. Waller EK. Cellular immunotherapy and cancer. Semin Oncol 2004; 31: 87-90.
11. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
12. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-819.
13. Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005; 105: 2594-2600.
14. Miller G, Bleier JI, Antonescu C, Pillarisetty VG, Shah AB, Lahrs S et al. Natural killer cell depletion confounds the antitumor mechanism of endogenous IL-12 overexpression. Int J Cancer 2004; 110: 395-402.
15. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835-1838.
16. Luhm J, Brand JM, Koritke P, Hoppner M, Kirchner H, Frohn C. Large-scale generation of natural killer lymphocytes for clinical application. J Hematother Stem Cell Res 2002; 11: 651-657.
17. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood 2005; 105: 3051-3057.
18. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99: 3661-3667.
19. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L et al. Ligands for natural killer cell activating receptors are expressed upon maturation of normal myelomonocytic cells but are low in acute myeloid leukemias. Blood 2005; 105: 3615-3622.
20. Kalberer CP, Siegler U, Wodnar-Filipowicz A. Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells. Blood 2003; 102: 127-135.
21. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: Implications for the innate immune response. J Immunol 1999; 162: 4511-4520.
22. Verlinden SF, van Es HH, van Bekkum DW. Serial bone marrow sampling for long-term follow up of human hematopoiesis in NOD/SCID mice. Exp Hematol 1998; 26: 627-630.
23. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
24. Lowdell MW, Lamb L, Hoyle C, Velardi A, Prentice HG. Non-MHC-restricted cytotoxic cells: Their roles in the control and treatment of leukaemias. Br J Haematol 2001; 114: 11-24.
25. Torelli GF, Guarini A, Palmieri G, Breccia M, Vitale A, Santoni A et al. Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. Br J Haematol 2002; 116: 299-307.
26. Verfaillie C, Kay N, Miller W, McGlave P. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood 1990; 76: 401-408.
27. Pierson BA, Miller JS. The role of autologous natural killer cells in chronic myelogenous leukemia. Leuk Lymphoma 1997; 27: 387-399.
28. Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002; 117: 821-827.
29. Chklovskaia E, Nowbakht P, Nissen C, Gratwohl A, Bargetzi M, Wodnar-Filipowicz A. Reconstitution of dendritic, natural killer-cell subsets after allogeneic stem cell transplantation: Effects of endogenous flt3 ligand. Blood 2004; 103: 3860-3868.
30. Robertson LE, Denny AW, Huh YO, Plunkett W, Keating MJ, Nelson JA. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Cancer Chemother Pharmacol 1996; 37: 445-450.
31. Verheyden S, Bernier M, Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 2004; 18: 2002-2007.
32. Brouwer RE, van der Heiden P, Schreuder GM, Mulder A, Datema G, Anholts JD et al. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol 2002; 63: 200-210.
33. Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH et al. Down-regulation of HLA-A, HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: An escape mechanism from CTL, NK attack? Blood 2004; 103: 3122-3130.
34. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D, T-cell activation. Nature 2002; 419: 734-738.
35. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46, natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999; 29: 1656-1666.
36. Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W et al. ULBP1, 2, 3: Novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol 2001; 31: 1428-1437.
37. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG et al. Functional expression, release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389-1396.
38. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
39. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999; 94: 1761-1772.
40. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1, H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-171.
41. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells, up-regulated by trans-retinoic acid. Cancer Res 2004; 64: 9172-9179.
42. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
43. Burnett AK. Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - an adult treater's view. Br J Haematol 2002; 118: 357-364.
44. Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, Tonn T et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33: 261-266.
45. Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 1999; 85: 1506-1513.
46. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2, interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002; 13: 169-183.